Literature DB >> 19144661

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach.

John M Bennett1, Attilio Orazi.   

Abstract

Members of the French-American-British Cooperative Leukemia Working Group met to review cases of aplastic anemia, hypocellular myelodysplastic syndrome and hypocellular acute myeloid leukemia. Criteria were proposed and modified following three workshops. Additional input was obtained from another hematopathologist with a special interest in bone marrow histology and immunohistochemistry. Guidelines were recommended based on the workshop results as well as additional studies including selective immunohistochemistry, flow cytometry and cytogenetics.

Entities:  

Mesh:

Year:  2009        PMID: 19144661      PMCID: PMC2635414          DOI: 10.3324/haematol.13755

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

1.  Biologic characteristics of patients with hypocellular myelodysplastic syndromes.

Authors:  R Goyal; H Qawi; I Ali; S Dar; S Mundle; V Shetty; Y Mativi; K Allampallam; L Lisak; J Loew; P Venugopal; S Gezer; E Robin; S Rifkin; A Raza
Journal:  Leuk Res       Date:  1999-04       Impact factor: 3.156

2.  NORMAL VARIATIONS WITH AGING OF THE AMOUNT OF HEMATOPOIETIC TISSUE IN BONE MARROW FROM THE ANTERIOR ILIAC CREST. A STUDY MADE FROM 177 CASES OF SUDDEN DEATH EXAMINED BY NECROPSY.

Authors:  R J HARTSOCK; E B SMITH; C S PETTY
Journal:  Am J Clin Pathol       Date:  1965-04       Impact factor: 2.493

3.  Hypocellular acute myeloid leukemia: the Rochester (New York) experience.

Authors:  N Tuzuner; C Cox; J M Rowe; J M Bennett
Journal:  Hematol Pathol       Date:  1995

4.  Reference standards for bone marrow cellularity.

Authors:  N Tuzuner; J M Bennett
Journal:  Leuk Res       Date:  1994-08       Impact factor: 3.156

5.  The histological characterization of ALIP in the myelodysplastic syndromes.

Authors:  C De Wolf-Peeters; R Stessens; V Desmet; G Tricot; R L Verwilghen
Journal:  Pathol Res Pract       Date:  1986-08       Impact factor: 3.250

6.  Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features.

Authors:  I Fohlmeister; R Fischer; B Mödder; M Rister; H E Schaefer
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

7.  Myelodysplastic syndrome in children and adolescents.

Authors:  Charlotte M Niemeyer; Irith Baumann
Journal:  Semin Hematol       Date:  2008-01       Impact factor: 3.851

8.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

Authors:  Elaine M Sloand; Colin O Wu; Peter Greenberg; Neal Young; John Barrett
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

9.  Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival.

Authors:  J E Goasguen; T Matsuo; C Cox; J M Bennett
Journal:  Leukemia       Date:  1992-06       Impact factor: 11.528

10.  Bone marrow cellularity in myeloid stem cell disorders: impact of age correction.

Authors:  N Tuzuner; C Cox; J M Rowe; J M Bennett
Journal:  Leuk Res       Date:  1994-08       Impact factor: 3.156

View more
  44 in total

1.  Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

Review 2.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

Review 3.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

4.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?

Authors:  S Nakao; R P Gale
Journal:  Leukemia       Date:  2016-09-02       Impact factor: 11.528

6.  Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients.

Authors:  Aref Al-Kali; Sergej Konoplev; Erpei Lin; Tapan Kadia; Stefan Faderl; Farhad Ravandi; Mohamad Ayoubi; Mark Brandt; Jorge E Cortes; Hagop Kantarjian; Gautam Borthakur
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

7.  Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.

Authors:  Jeffrey L Lew; Joshua L Fenderson; Mark G Carmichael
Journal:  Hawaii J Med Public Health       Date:  2017-11

8.  Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years.

Authors:  Vipul Sharad Sheth; Victoria Potter; Shreyans A Gandhi; Austin Gladston Kulasekararaj; Hugues de Lavallade; Petra Muus; Antonio Pagliuca; Carmel F M Rice; Varun Mehra; Francesco Grimaldi; Shafqat Inam; Linda D Barber; Ghulam J Mufti; Judith C Marsh
Journal:  Blood Adv       Date:  2019-10-22

Review 9.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

10.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.